vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Laird Superfood, Inc. (LSF). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $13.3M, roughly 1.1× Laird Superfood, Inc.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -13.2%, a 15.0% gap on every dollar of revenue. On growth, Laird Superfood, Inc. posted the faster year-over-year revenue change (15.0% vs 11.5%). Over the past eight quarters, Laird Superfood, Inc.'s revenue compounded faster (16.1% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
CSBR vs LSF — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $13.3M |
| Net Profit | $268.0K | $-1.8M |
| Gross Margin | 51.7% | 34.1% |
| Operating Margin | 1.2% | -13.5% |
| Net Margin | 1.8% | -13.2% |
| Revenue YoY | 11.5% | 15.0% |
| Net Profit YoY | -63.2% | -341.4% |
| EPS (diluted) | $0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $13.3M | ||
| Q3 25 | $14.0M | $12.9M | ||
| Q2 25 | $12.4M | $12.0M | ||
| Q1 25 | $17.0M | $11.7M | ||
| Q4 24 | $13.5M | $11.6M | ||
| Q3 24 | $14.1M | $11.8M | ||
| Q2 24 | $14.0M | $10.0M | ||
| Q1 24 | $12.0M | $9.9M |
| Q4 25 | $268.0K | $-1.8M | ||
| Q3 25 | $-436.0K | $-975.1K | ||
| Q2 25 | $-1.8M | $-362.2K | ||
| Q1 25 | $4.5M | $-156.2K | ||
| Q4 24 | $728.0K | $-398.4K | ||
| Q3 24 | $1.3M | $-166.1K | ||
| Q2 24 | $-109.0K | $-239.1K | ||
| Q1 24 | $-2.5M | $-1.0M |
| Q4 25 | 51.7% | 34.1% | ||
| Q3 25 | 42.9% | 36.5% | ||
| Q2 25 | 41.1% | 39.9% | ||
| Q1 25 | 61.2% | 41.9% | ||
| Q4 24 | 44.9% | 38.6% | ||
| Q3 24 | 49.7% | 43.0% | ||
| Q2 24 | 48.2% | 41.8% | ||
| Q1 24 | 34.7% | 40.0% |
| Q4 25 | 1.2% | -13.5% | ||
| Q3 25 | -3.8% | -7.7% | ||
| Q2 25 | -16.2% | -3.3% | ||
| Q1 25 | 26.4% | -1.9% | ||
| Q4 24 | 5.4% | -4.1% | ||
| Q3 24 | 9.5% | -2.3% | ||
| Q2 24 | -1.9% | -3.4% | ||
| Q1 24 | -21.4% | -11.0% |
| Q4 25 | 1.8% | -13.2% | ||
| Q3 25 | -3.1% | -7.6% | ||
| Q2 25 | -14.9% | -3.0% | ||
| Q1 25 | 26.4% | -1.3% | ||
| Q4 24 | 5.4% | -3.4% | ||
| Q3 24 | 9.3% | -1.4% | ||
| Q2 24 | -0.8% | -2.4% | ||
| Q1 24 | -21.1% | -10.3% |
| Q4 25 | $0.02 | — | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $0.31 | — | ||
| Q4 24 | $0.05 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $-0.01 | — | ||
| Q1 24 | $-0.19 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $5.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $11.5M |
| Total Assets | $30.2M | $19.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $5.1M | ||
| Q3 25 | $10.3M | $5.1M | ||
| Q2 25 | $9.8M | $3.9M | ||
| Q1 25 | $3.2M | $7.0M | ||
| Q4 24 | $2.8M | $8.3M | ||
| Q3 24 | $2.9M | $7.9M | ||
| Q2 24 | $2.6M | $7.6M | ||
| Q1 24 | $4.5M | $7.1M |
| Q4 25 | $4.2M | $11.5M | ||
| Q3 25 | $3.5M | $12.8M | ||
| Q2 25 | $3.8M | $13.4M | ||
| Q1 25 | $5.5M | $13.3M | ||
| Q4 24 | $681.0K | $13.2M | ||
| Q3 24 | $-332.0K | $13.1M | ||
| Q2 24 | $-1.9M | $12.6M | ||
| Q1 24 | $-2.1M | $12.7M |
| Q4 25 | $30.2M | $19.2M | ||
| Q3 25 | $30.5M | $18.9M | ||
| Q2 25 | $32.3M | $20.4M | ||
| Q1 25 | $30.6M | $21.5M | ||
| Q4 24 | $25.2M | $19.3M | ||
| Q3 24 | $24.9M | $18.8M | ||
| Q2 24 | $26.1M | $18.0M | ||
| Q1 24 | $26.8M | $17.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $68.4K |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -13.1% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $68.4K | ||
| Q3 25 | $600.0K | $1.2M | ||
| Q2 25 | $6.9M | $-2.8M | ||
| Q1 25 | $490.0K | $-1.3M | ||
| Q4 24 | $-283.0K | $339.2K | ||
| Q3 24 | $311.0K | $305.8K | ||
| Q2 24 | $-1.8M | $642.7K | ||
| Q1 24 | $-919.0K | $-422.3K |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $554.0K | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | -13.1% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -8.4% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
